|
|
Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study
A. Amiot
,
A. Vered
,
J. Filippi
,
G. Cadiot
,
D. Laharie
,
et al.
Journal of Crohn's and Colitis, 2020, 14 (1), pp.S579
Article dans une revue
hal-03552084v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.
Aline Derosiere
,
Vincent Nicolai
,
David Malka
,
Astrid Pozet
,
Julien Lazartigues
,
et al.
Article dans une revue
hal-03606012v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)
A. Buisson
,
Mathurin Fumery
,
M. Serrero
,
L. Orsat
,
S. Nancey
,
et al.
2020, pp.S337-S338
Autre publication scientifique
hal-03551532v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease
S. Tadbiri
,
M. Nachury
,
Y. Bouhnik
,
M. Serrero
,
F. Jerome
,
et al.
Journal of Crohn's and Colitis, 2020, 14 (1), pp.S272
Article dans une revue
hal-03551538v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study
C. Rayer
,
X. Roblin
,
D. Laharie
,
Benoît Caron
,
M. Flamant
,
et al.
Article dans une revue
hal-03551537v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|